Benno P, Alam M, Henriksson K, Norin E, Uribe A, Midtvedt T
Department of Internal Medicine, Danderyd Hospital, Sweden.
Scand J Rheumatol. 1994;23(6):311-5. doi: 10.3109/03009749409099279.
The aim of this study was to examine the microflora-associated characteristics (MACs) of faecal samples of patients with rheumatoid arthritis (RA) and to evaluate the actions of sulphasalazine (SASP) on these MACs. The conversion of cholesterol to coprostanol, the production of urobilinogen, the degradation of faecal tryptic activity (FTA) and of beta-aspartylglycine were measured in faecal samples from 19 patients treated with SASP and 21 patients not treated with this medication. A control group of 21 healthy subjects was sex- and age-matched with the untreated patients. The conversion of cholesterol to coprostanol showed a bimodal distribution. The frequency of high converters in patients without SASP treatment was higher than in healthy subjects (p < 0.05). Treatment with SASP markedly increased the FTA and reduced the urobilinogen values, as compared to the untreated patients (p < 0.05). Beta-aspartylglycine was not found in any faecal samples. The results indicate that patients with RA have an abnormal formation of coprostanol, which is ascribed to alterations in the function of the Eubacteria species. In patients with RA, SASP treatment induces disturbances in the metabolism of the microflora.
本研究旨在检测类风湿关节炎（RA）患者粪便样本的微生物群相关特征（MACs），并评估柳氮磺胺吡啶（SASP）对这些MACs的作用。在19例接受SASP治疗的患者和21例未接受该药物治疗的患者的粪便样本中，检测了胆固醇向粪甾烷醇的转化、尿胆原的产生、粪便胰蛋白酶活性（FTA）和β-天冬氨酰甘氨酸的降解情况。选取21名健康受试者作为对照组，其性别和年龄与未治疗患者相匹配。胆固醇向粪甾烷醇的转化呈双峰分布。未接受SASP治疗的患者中高转化率的频率高于健康受试者（p<0.05）。与未治疗患者相比，SASP治疗显著提高了FTA并降低了尿胆原值（p<0.05）。在任何粪便样本中均未检测到β-天冬氨酰甘氨酸。结果表明，RA患者粪甾烷醇形成异常，这归因于真细菌种类功能的改变。在RA患者中，SASP治疗会引起微生物群代谢紊乱。
